CONy 2020 Parkinson’s disease Program
Section Heads:
*This program is subject to change
| Saturday, March 28, 2020 | |
| 08:30-10:10 | CONTROVERSIES IN ADVANCED PD |
| 08:30-09:20 | DBS effectiveness against nonmotor features in PD is similar to those of infusion therapies. |
| Capsule: DBS and infusion therapies are both recognized as therapeutic approaches in the treatment of motor symptoms in advanced stage PD when patients develop “wearing off” and/or dyskinesias with oral dopaminergic medication. However, the effects of these two therapeutic approaches on nonmotor features are still under debate, but seem to have similar beneficial effects. | |
| 08:30-08:40 | Host: Fiona Gupta, USA |
| 08:40-08:55 | Yes: Abdelhamid Benazzouz, France |
| 08:55-09:10 | No: Keyoumars Ashkan, UK |
| 09:10-09:20 | Discussion and rebuttals |
| 09:20-10:10 | When is the right time to refer PD patients for deep brain stimulation? |
| Capsule: Deep brain stimulation(DBS) is effective in treating of medication-refractory symptoms (motor and non-motor) and improving patients’ quality of life in advanced Parkinson’s disease (PD).Currently, it is usually performed in late stage of PD. Advances in our understanding of the natural history of the disease, improved surgical techniques, brain imaging, short and long-term safety profile and device design require us to re-evaluate the right time for DBS to earlier stages of the disease than for which it is currently used and to confer long-term symptomatic benefit for patients | |
| 09:20-09:30 | Host: Mike Samuel, UK |
| 09:30-09:45 | Late: Patricia Limousin, UK |
| 09:45-10:00 | Early: Vladimira Vuletic, Croatia |
| 10:00-10:10 | Discussion and rebuttals |
| 10:10-10:25 | Coffee Break |
| 10:25-12:05 | CONTROVERSIES IN CLINICAL APPROACH |
| 10:25-11:15 | Clinical assessment in PD – Motor assessment is the key and nonmotor is not required |
| 10:25-10:35 | Host: Irene Litvan, USA |
| 10:35-10:50 | Yes: |
| 10:50-11:05 | No: Pedro Garcia Ruiz, Spain |
| 11:05-11:15 | Discussion and rebuttals |
| 11:15-12:05 | Should untroubling dyskinesia be treated? |
| Capsule: Over several years, evidence has been accumulating that suggests vascular disease impacts on common causes of dementia, in particular Alzheimer’s disease. Modifiable vascular risk factors such as hypertension, diabetes, dyslipidaemia and adiposity are all linked to Alzheimer’s disease. However, it is unclear whether these factors contribute to or promote Alzheimer’s disease pathology and neurodegeneration. This debate will address whether vascular changes are just coincident with Alzheimer type of pathology or part and parcel of Alzheimer’s disease. | |
| 11:15-11:25 | Host: Daniel Kremens, USA |
| 11:25-11:40 | Yes: Rajesh Pahwa, USA |
| 11:40-11:55 | No: Ray Chaudhuri, UK |
| 11:55-12:05 | Discussion and rebuttals |
| 12:15-13:15 | Industry Supported Symposium |
| 13:15-14:15 | Lunch Break |
| 13:15-14:15 | Meet the Expert |
| 14:15-15:45 | CONTROVERSIES IN THERAPEUTIC STRATEGIES |
| 14:15-14:55 | Should PD patients carrying (GBA) mutations be treated differently from gene negative? |
| 14:15-14:25 | Host: Vladimira Vuletic, Croatia |
| 14:25-14:35 | Yes: Anthony Schapira, UK |
| 14:35-14:45 | No: Rajesh Pahwa, USA |
| 14:45-14:55 | Discussion and rebuttals |
| 14:55-15:45 | Is continuous dopaminergic stimulation better strategy than pulsatile in every patient? |
| 14:55-15:05 | Host: Fernando Pagan, USA |
| 15:05-15:20 | Yes: Stuart Isaacson, USA |
| 15:20-15:35 | No: Tatyana Simuni, USA |
| 15:35-15:45 | Discussion and rebuttals |
| 15:45-16:00 | Coffee Break |
| 16:00-19:00 | CONTROVERSIES IN PD ETIOPATHOGENESIS |
| 16:00-16:50 | Is CSF alpha-snyuclein a useful biomarker for PD? |
| Capsule: A change in the content of α-synuclein (α-SN) in CSF is considered as a promising biomarker of PD. Indeed, the total α-SN content in CSF decreases, and the fractions of phosphorylated and oligomeric α-SN increase in PD compared to aging control. However, all attempts to use α-SN as a biomarker for differential diagnosis or prognosis of progression and severity were unsuccessful. It is hoped that α-SN in CSF can be used as a biomarker for the differential diagnosis of PD, but only in combination with biomarkers of other diseases. | |
| 16:00-16:10 | Host: Michael Ugrumov, Russia |
| 16:10-16:25 | Yes: Georgia Xiromerisiou, Greece |
| 16:25-16:40 | No: Mark F. Lew, USA |
| 16:40-16:50 | Discussion and rebuttals |
| 16:50-17:40 | Are there important environmental factors for PD? |
| Capsule: The etiology of the neurodegenerative processes which characterize idiopathic Parkinson’s disease (PD) is not fully understood. Although several genes were found responsible for the development of PD, the causative agents for a great percent of cases remain unclear. Various factors were incriminated to increase the risk of PD development. The possible interaction between environmental and genetic factors is thought to play an important role in PD pathogenesis. | |
| 16:50-17:00 | Host: Alastair Noyce, UK |
| 17:00-17:15 | Yes: Cristian Falup-Pecurariu, Romania |
| 17:15-17:30 | No: Zvezdan Pirtosek, Slovenia |
| 17:30-17:40 | Discussion and rebuttals |
| 17:40-18:10 | The personalized Parkinson’s Ray Chaudhuri, UK |
| 18:10-18:15 | Discussion |
| 18:15-19:00 | Clinical pathological conference (CPC) – organized by Tamas Revesz –CBD case with a PSP clinical phenotype (CBD-PSPS) Tom Warner, Queen Square – Helen Ling, UK |